The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study desig

This novel approach may lead to a new treatment for those with ischemic heart disease suffering from medically refractory heart failure.